News

Lung Cancer Research Foundation Announces Request for Proposals Focused on Curing EGFR Mutant Lung Cancers
The Lung Cancer Research Foundation (LCRF) announces today a new funding mechanism: the 2025 LCRF Team Science Award on Advancing Therapies Toward Curing EGFR Mutated Lung Cancers. The Request for ...
Fierce Biotech6h
Mineralys' hypertension drug continues winning streak, lowering blood pressure in phase 2
The latest clinical win follows a dual set of phase 3 and phase 2 results back in March. In that data drop, Mineralys reported that lorundrostat reduced systolic blood pressure in a late-stage study ...
Taiwan News14h
Vivoryon Therapeutics N.V. Q1 2025 Financial Results and Operational Progress
On April 29, 2025, Vivoryon disclosed preclinical data from a series of experiments in a chronic kidney disease animal model, analyzing different treatment regimens of varoglutamstat in combination ...
Market Inference2h
Mineralys Therapeutics Reports Positive Phase 2 Results
Mineralys Therapeutics, Inc. (NASDAQ: MLYS) has announced positive topline results from its phase 2 Explore-CKD trial of ...
Lung Cancer Research Foundation Announces New Research Collaboration with Boehringer Ingelheim
The Lung Cancer Research Foundation (LCRF) announces today a new research collaboration with Boehringer Ingelheim creating two funding mechanisms designed to address HER2 mutations in lung cancer: a ...